Free Newsletter
Novavax shares spike on new vaccine success
Shares of Novavax spiked 21 percent after the company announced that it was able to create a swine flu vaccine with its virus-like particle technology in only 11 weeks.
"Demonstration of our ability to construct and produce GMP-quality influenza vaccine within 12 weeks under real pandemic conditions is an important and successful test of our VLP technology," Jim Robinson, vice president of manufacturing and quality operations at Novavax, said in a statement. VLP technology uses an artificial virus that doesn't contain the genetic material required for transmission.
Novavax has completed a Phase I/IIa clinical study with a candidate H5N1 influenza VLP vaccine and is currently in Phase II trials with a VLP based seasonal flu vaccine candidate. The company plans to initiate a Phase II study with its seasonal flu vaccine candidate in the elderly population during Q4.
- read the story from Reuters
Related Articles:
Deals help Novavax pay off $22M in debts
Novavax shares skyrocket on European vax pact
Novavax shares soar on NIH swine flu agreement
Novavax gets $11M, forges Indian joint venture
Comments
Post new comment
Paid Research Reports
- Pricing and Reimbursement: Innovative Risk-Sharing Strategies
- Emerging Markets Series: The Pharmaceutical Market of Poland
- The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses
- New Approaches to Pharma R&D;: Evolving strategies to rejuvenate R&D; efficiency
- Stakeholder Opinions: Vaccine antigen delivery technologies - Molecular systems to open new markets
- The Top 10 Contract Research Organizations
More Research Reports >>
Click here to get the FierceVaccines email newsletter for FREE!
Be the first to comment